Suchen
NovaBay Pharmaceuticals Inc
NBYZur Watchlist hinzufügen
1.950USD
0.0000.00%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
68.61MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über NovaBay Pharmaceuticals Inc Unternehmen
NovaBay Pharmaceuticals, Inc. is engaged in wound care products. The Company manufactures and sells its proprietary form of hypochlorous acid for the wound care market through its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries.
NovaBay Pharmaceuticals Inc Informationen
BörsenkürzelNBY
Name des UnternehmensNovaBay Pharmaceuticals Inc
IPO-datumOct 26, 2007
CEOKazley (Michael John)
Anzahl der mitarbeiter14
WertpapierartOrdinary Share
GeschäftsjahresendeOct 26
Addresse2000 Powell St Ste 1150
StadtEMERYVILLE
BörseNASDAQ OMX – NASDAQ Basic Amex
LandUnited States of America
Postleitzahl94608-1804
Telefon15108998800
Websitehttps://novabay.com/
BörsenkürzelNBY
IPO-datumOct 26, 2007
CEOKazley (Michael John)
Führungskräfte von NovaBay Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
172.00
-10.47%
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
6.00
+16.67%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
Mr. Michael Kazley
Mr. Michael Kazley
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Swan Sit
Ms. Swan Sit
Independent Director
Independent Director
172.00
-10.47%
Mr. Tommy Law
Mr. Tommy Law
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
6.00
+16.67%
Mr. Paul E. Freiman, Ph.D.
Mr. Paul E. Freiman, Ph.D.
Director
Director
--
--
Mr. Justin M. Hall, Esq.
Mr. Justin M. Hall, Esq.
Vice President - Business Development, General Counsel, Corporate Secretary
Vice President - Business Development, General Counsel, Corporate Secretary
--
--
Dr. Yenyou (Jeff) Zheng, Ph.D.
Dr. Yenyou (Jeff) Zheng, Ph.D.
Independent Director
Independent Director
--
--
Capt. Jody Cain
Capt. Jody Cain
IR Contact Officer
IR Contact Officer
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von NovaBay Pharmaceuticals Inc?
Die fünf größten Anteilseigner von NovaBay Pharmaceuticals Inc sind: Ms. Swan Sit
Wie viele Institutionen halten Anteile an NovaBay Pharmaceuticals Inc (NBY)?
Mit Stand vom 2026Q1 halten 47 Institutionen Anteile an NovaBay Pharmaceuticals Inc, mit einem Gesamtmarktwert von etwa 1.80M, was 6.77% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 1464094.00 gestiegen.